OWL 0.19CIGI.TO 3.61DOL.TO -0.07CRCL 0CLS.TO 55.23ZGI.TO -0.09XMW.TO 0.31
Daily Stock Opinions and Ratings
Stockchase Opinions

Cameron HurstISHARES DOW JONES US MEDICAL DEV.(ETF)IHIPAST TOP PICKJul 10, 2019

(A Top Pick Jul 11/18, Up 19%) A great example of demographic and diabetes trends that has created huge growth in demand. A sad, but profitable story. Not a defensive stock and has beta with the market.
Cameron HurstCameron Hurst
Owned
Unlock Rating
$243.33

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Aug 11, 2025

Healthcare is not a value trap. It's the worst performing sector this year--and could get worse--but the knife has fallen. If you're looking for something to buy in a market with high valuations and possible headlines from inflation prints, look at healthcare. Healthcare is insulated from interest rate volatility. If you're worried about Trump's attitude to phama, then look at healthcare equipment and services and buy IHI.

Photo of Liz Young, Head of investment strategy at SoFiLiz Young, Head of investment strategy at SoFiUnlock Rating
$61.11

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Aug 30, 2022
Allan Tong’s Discover Picks IHI's MER is actually higher (at 0.39%) than the yield it pays (0.3%). Like the other names here, IHI trades at a low beta, 0.86 to be precise. So, if you're not buying this for income, what's the growth? Let's look at IHI's largest holdings. TMO offers diversity among lab testing, lab equipment and diagnostics and typically trades at a premium multiple. TMO was a hit in the Covid-testing days, but that stereotype has stuck with them. The company reported a strong quarter a month ago, but that didn't move the needle. TMO shares have been choppy but rangebound all year, but if Wall Street gets gospel on TMO, share should pop. The price target is 20% higher at $674. Read 3 Best U.S. Healthcare ETFs for our full analysis.
Photo of Stockchase DiscoverStockchase DiscoverUnlock Rating
$50.54

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
BUY ON WEAKNESS

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Apr 04, 2022
Likes medical devices and health area as society ages. Would buy during a correcting. US and Europe have good healthcare stocks.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$61.11

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Aug 03, 2021

Happy to own this, outperforming XLV, for instance. It's diversified. ZUH is another option, because it covers pharmas, hospital management and other areas. IHI, as a hospital provider, is pretty good.

Photo of John HoodJohn Hood
Owned
Unlock Rating
$63.49

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Apr 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

Photo of David BurrowsDavid BurrowsUnlock Rating
$360.73

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
PARTIAL SELL

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Nov 03, 2020
This ETF has smashed it over the past 5 years. Medical devices are a hybrid of tech and healthcare, which he really likes. Problem is that market enthusiasm and growth are priced in here already (like the FAANGs). Take profits.
Photo of Tyler MordyTyler MordyUnlock Rating
$307.02

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Apr 08, 2020
It specializes in medical devices and equipment. He has held this over a year and a half. He likes the diversification it offers. He is not sure which of the holdings are involved in manufacturing defibrillators.
Photo of John HoodJohn Hood
Owned
Unlock Rating
$239.74

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
DON'T BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Feb 25, 2020
It's very nichy, though it offers good exposure to healthcare. It's a high-beta play on healthcare, biotech and medical devices. His main worry is uncertainty around the US election, namely Bernie Sanders. If he nationalizes medical care, then this ETF will suffer.
Photo of Tyler MordyTyler MordyUnlock Rating
$256.90

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
BUY

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Dec 27, 2019
He likes medical devices a lot. The ETF looks good with reasonable MER. Once the rhetoric from the presidential campaign subsides, it’ll probably have more smooth sailing.
Photo of Richard CroftRichard Croft
No
Unlock Rating
$264.96

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
PAST TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Oct 03, 2019
(A Top Pick Oct 16/18, Up 16%) It continues to work. Everything is going right with this one. It is not a defensive name and while he likes it, he would not have more than a few percent of it in the market.
Photo of Cameron HurstCameron Hurst
No
Unlock Rating
$241.94

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Oct 03, 2019
He loves it. It was flat over the last quarter. He is sticking with it.
Photo of Cameron HurstCameron Hurst
Owned
Unlock Rating
$241.94

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
PAST TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Sep 13, 2019

(A Top Pick Aug 15/18, Up 20%) A good way to play pharma without the litigation problems. For a Canadian one, it would be ZUH. Medical devices have done very well, and wish he had more.

Photo of John HoodJohn Hood
Owned
Unlock Rating
$248.79

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Sep 11, 2019
A perennial favorite for him. Worldwide hospital spending, global spending and Type II diabetes on the rise all make this a good holding. It is fairly high beta, so if the market falls this will fall too. Yield 0.31%
Photo of Cameron HurstCameron Hurst
Owned
Unlock Rating
$248.42

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s
TOP PICK

ISHARES DOW JONES US MEDICAL DEV.(ETF)(IHI)

Aug 07, 2019
The only area of healthcare he remains invested in. The demographics are creating tailwinds. An aging population and growing obesity is good for this. Good cash flow holdings and good diversification. Yield 0.32%
Photo of Cameron HurstCameron Hurst
Owned
Unlock Rating
$241.31

Stock price when the opinion was issued

$48.84

As of Jun 01, 2026. Market Open.

E.T.F.'s

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

QBTS -0.96$29.18
BB.TO 1.08$13.44
ZIM 1.23$24.72
NOK 1.41$16.25
BE -11.49$273.51

Today's Top Picks

OWL 0.19$10.47
CIGI.TO 3.61$133.72
DOL.TO -0.07$176.23
CRCL 0$
CLS.TO 55.23$588.24

Popular Articles

Latest Sell Signals

PSIX -2.3$39.38
WFC -0.37$77.17
EQX.TO -1.54$17.26
UNH -0.45$379.86
TD.TO 0.05$17.36

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Teal Linde

Teal Linde

Linde Equity Report

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Karen Firestone, CEO, Aureus Asset Management

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica